JP2021006586A - Scalp agents - Google Patents
Scalp agents Download PDFInfo
- Publication number
- JP2021006586A JP2021006586A JP2020176420A JP2020176420A JP2021006586A JP 2021006586 A JP2021006586 A JP 2021006586A JP 2020176420 A JP2020176420 A JP 2020176420A JP 2020176420 A JP2020176420 A JP 2020176420A JP 2021006586 A JP2021006586 A JP 2021006586A
- Authority
- JP
- Japan
- Prior art keywords
- collagen
- scalp
- overproduction
- group
- horse chestnut
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004761 scalp Anatomy 0.000 title claims abstract description 28
- 108010035532 Collagen Proteins 0.000 claims abstract description 58
- 102000008186 Collagen Human genes 0.000 claims abstract description 58
- 229920001436 collagen Polymers 0.000 claims abstract description 58
- 238000012261 overproduction Methods 0.000 claims abstract description 47
- 239000003112 inhibitor Substances 0.000 claims abstract description 17
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 7
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 7
- 244000173853 Sanguisorba officinalis Species 0.000 claims abstract 2
- 235000008282 Sanguisorba officinalis Nutrition 0.000 claims abstract 2
- 239000000284 extract Substances 0.000 claims description 17
- 241000196324 Embryophyta Species 0.000 claims description 6
- 235000010181 horse chestnut Nutrition 0.000 abstract description 38
- 210000002950 fibroblast Anatomy 0.000 abstract description 16
- 244000105059 Geranium thunbergii Species 0.000 abstract description 13
- 235000005491 Geranium thunbergii Nutrition 0.000 abstract description 13
- 240000000691 Houttuynia cordata Species 0.000 abstract description 12
- 235000013719 Houttuynia cordata Nutrition 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- 240000007594 Oryza sativa Species 0.000 abstract description 9
- 235000007164 Oryza sativa Nutrition 0.000 abstract description 9
- 235000006886 Zingiber officinale Nutrition 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 8
- 235000008397 ginger Nutrition 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 6
- 235000008440 Crataegus cuneata Nutrition 0.000 abstract description 5
- 244000160089 Crataegus cuneata Species 0.000 abstract description 5
- 241000208690 Hamamelis Species 0.000 abstract description 5
- 244000025221 Humulus lupulus Species 0.000 abstract description 5
- 239000002537 cosmetic Substances 0.000 abstract description 5
- 244000166124 Eucalyptus globulus Species 0.000 abstract description 4
- 235000016639 Syzygium aromaticum Nutrition 0.000 abstract description 4
- 235000003373 curcuma longa Nutrition 0.000 abstract description 4
- 235000008694 Humulus lupulus Nutrition 0.000 abstract description 3
- 244000223014 Syzygium aromaticum Species 0.000 abstract description 3
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract description 2
- 235000008708 Morus alba Nutrition 0.000 abstract description 2
- 240000000249 Morus alba Species 0.000 abstract description 2
- 241001092459 Rubus Species 0.000 abstract 2
- 241000157280 Aesculus hippocastanum Species 0.000 abstract 1
- 235000003884 Aspalathus contaminatus Nutrition 0.000 abstract 1
- 240000006914 Aspalathus linearis Species 0.000 abstract 1
- 235000012984 Aspalathus linearis Nutrition 0.000 abstract 1
- 235000002992 Betula pubescens Nutrition 0.000 abstract 1
- 241001520764 Betula pubescens Species 0.000 abstract 1
- 235000021513 Cinchona Nutrition 0.000 abstract 1
- 241000157855 Cinchona Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 235000021511 Cinnamomum cassia Nutrition 0.000 abstract 1
- 241000555678 Citrus unshiu Species 0.000 abstract 1
- 241000218203 Coptis japonica Species 0.000 abstract 1
- 244000163122 Curcuma domestica Species 0.000 abstract 1
- 241000195480 Fucus Species 0.000 abstract 1
- 235000017309 Hypericum perforatum Nutrition 0.000 abstract 1
- 244000141009 Hypericum perforatum Species 0.000 abstract 1
- 241001365031 Isodon japonicus Species 0.000 abstract 1
- 244000052585 Rosa centifolia Species 0.000 abstract 1
- 235000016588 Rosa centifolia Nutrition 0.000 abstract 1
- 235000000656 Rosa multiflora Nutrition 0.000 abstract 1
- 244000050053 Rosa multiflora Species 0.000 abstract 1
- 239000004902 Softening Agent Substances 0.000 abstract 1
- 241000246044 Sophora flavescens Species 0.000 abstract 1
- 244000081822 Uncaria gambir Species 0.000 abstract 1
- 235000009392 Vitis Nutrition 0.000 abstract 1
- 241000219095 Vitis Species 0.000 abstract 1
- 244000273928 Zingiber officinale Species 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 229940127554 medical product Drugs 0.000 abstract 1
- 239000001841 zingiber officinale Substances 0.000 abstract 1
- 241000157282 Aesculus Species 0.000 description 37
- 230000037319 collagen production Effects 0.000 description 27
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 24
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 20
- 230000002401 inhibitory effect Effects 0.000 description 19
- 239000002904 solvent Substances 0.000 description 17
- 239000000419 plant extract Substances 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 229940058015 1,3-butylene glycol Drugs 0.000 description 10
- 235000019437 butane-1,3-diol Nutrition 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 235000009566 rice Nutrition 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 6
- 244000004281 Eucalyptus maculata Species 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 6
- 241000234314 Zingiber Species 0.000 description 6
- 235000017803 cinnamon Nutrition 0.000 description 6
- 230000004761 fibrosis Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
- 235000011201 Ginkgo Nutrition 0.000 description 5
- -1 aliphatic alcohols Chemical class 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 210000003780 hair follicle Anatomy 0.000 description 5
- 235000016623 Fragaria vesca Nutrition 0.000 description 4
- 240000009088 Fragaria x ananassa Species 0.000 description 4
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 3
- 235000003392 Curcuma domestica Nutrition 0.000 description 3
- 244000008991 Curcuma longa Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000011034 Rubus glaucus Nutrition 0.000 description 3
- 235000009122 Rubus idaeus Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000003176 fibrotic effect Effects 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 235000013976 turmeric Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000228673 Asarum europaeum Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000208680 Hamamelis mollis Species 0.000 description 2
- 239000009141 Houttuynia cordata plant extract Substances 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 240000007651 Rubus glaucus Species 0.000 description 2
- 241001125048 Sardina Species 0.000 description 2
- 241000219094 Vitaceae Species 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000003510 anti-fibrotic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000021021 grapes Nutrition 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 235000019512 sardine Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940118846 witch hazel Drugs 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 244000141218 Alpinia officinarum Species 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 241000219430 Betula pendula Species 0.000 description 1
- 235000009109 Betula pendula Nutrition 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 241000195950 Equisetum arvense Species 0.000 description 1
- 239000005768 Equisetum arvense L. Substances 0.000 description 1
- 244000061408 Eugenia caryophyllata Species 0.000 description 1
- 241000208152 Geranium Species 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 235000000665 Lycianthes asarifolia Nutrition 0.000 description 1
- 241000866517 Lycianthes asarifolia Species 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 241000109365 Rosa arkansana Species 0.000 description 1
- 235000005066 Rosa arkansana Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 235000020230 cinnamon extract Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000020708 ginger extract Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical group C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 1
- 229960003073 pirfenidone Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 244000089265 zong er cha Species 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、コラーゲン過剰産生抑制剤を含む、頭皮柔軟剤に関する。 The present invention relates to a scalp softener, including a collagen overproduction inhibitor.
線維芽細胞が産生するコラーゲンは、皮膚の弾性を保つために重要である。しかし炎症により線維芽細胞がTGF-β等の刺激を受けると、コラーゲン産生が過剰になり、コラーゲンの沈着や線維芽細胞の増生を特徴とした線維化が生じる（非特許文献１）。線維化した皮膚は、柔軟性を失い硬化する（非特許文献１）。 Collagen produced by fibroblasts is important for maintaining the elasticity of the skin. However, when fibroblasts are stimulated by TGF-β or the like due to inflammation, collagen production becomes excessive, and fibrosis characterized by collagen deposition and fibroblast proliferation occurs (Non-Patent Document 1). Fibrotic skin loses flexibility and hardens (Non-Patent Document 1).
TGF-β1は、毛包の毛乳頭細胞から分泌される脱毛因子としても知られている（特許文献１）。TGF-β1は、線維芽細胞を男性ホルモンで刺激した際にも増加し、コラーゲン産生を亢進させる（非特許文献２）。実際に、男性型脱毛症患者の頭皮では、脱毛領域の毛包周囲に線維化が認められる（特許文献２、非特許文献３〜５）。線維化した領域は、毛包伸長の物理的障壁となって発毛剤による治療応答性の低下（非特許文献４）、頭皮の血流の低下、毛母細胞の活性低下等（特許文献２）を招くことが示唆されている。そのため、頭皮の線維化を予防又は改善し、頭皮を柔軟化する成分の開発が期待されている（特許文献２）。 TGF-β1 is also known as a hair loss factor secreted from dermal papilla cells of hair follicles (Patent Document 1). TGF-β1 also increases when fibroblasts are stimulated with androgens and enhances collagen production (Non-Patent Document 2). In fact, in the scalp of a male pattern baldness patient, fibrosis is observed around the hair follicle in the hair loss region (Patent Document 2, Non-Patent Documents 3 to 5). The fibrotic region acts as a physical barrier to hair follicle elongation, resulting in decreased treatment response by a hair growth agent (Non-Patent Document 4), decreased blood flow in the scalp, decreased activity of hair matrix cells, etc. (Patent Document 2). ) Is suggested. Therefore, it is expected to develop a component that prevents or improves fibrosis of the scalp and softens the scalp (Patent Document 2).
頭皮を柔軟化するには、コラーゲンの異常蓄積を抑制して線維化を解消することが有効である（特許文献２）。今までに、頭皮を柔軟化するために、皮膚の角質層にスチームを浸透させる方法等が行われているが（特許文献３）、スチームを浸透させる方法が必ずしもコラーゲン過剰産生抑制作用を有するわけではない。また、線維化した組織の治療には、例えば、抗炎症薬が使用されてきた（非特許文献６）。しかし、抗炎症成分は必ずしも抗線維化作用を有するとは限らず（非特許文献７）、既知の抗炎症成分の線維化予防又は改善効果は充分とはいえない。抗線維化薬としてはピルフェニドンがあり、TGF-β1刺激した線維芽細胞のコラーゲン過剰産生抑制作用等により、線維化を改善する（非特許文献８）。しかし副作用の観点から、さらに安全性の高い成分の開発が望まれている。 In order to soften the scalp, it is effective to suppress abnormal accumulation of collagen and eliminate fibrosis (Patent Document 2). So far, in order to soften the scalp, a method of infiltrating steam into the stratum corneum of the skin has been performed (Patent Document 3), but the method of infiltrating steam does not necessarily have a collagen overproduction inhibitory effect. is not. In addition, for example, anti-inflammatory agents have been used for the treatment of fibrotic tissue (Non-Patent Document 6). However, the anti-inflammatory component does not always have an anti-fibrotic effect (Non-Patent Document 7), and the effect of preventing or improving the fibrosis of the known anti-inflammatory component is not sufficient. As an antifibrotic drug, there is pirfenidone, which improves fibrosis by suppressing collagen overproduction of TGF-β1-stimulated fibroblasts (Non-Patent Document 8). However, from the viewpoint of side effects, the development of safer ingredients is desired.
本発明の目的は、線維芽細胞のコラーゲン過剰産生を抑制する素材を提供することである。さらには、頭皮の毛包部の線維芽細胞のコラーゲン過剰産生を抑制する素材を提供することである。本発明のもう一つの目的は、コラーゲン過剰産生抑制剤を含有する頭皮柔軟剤を提供することである。 An object of the present invention is to provide a material that suppresses collagen overproduction of fibroblasts. Furthermore, it is to provide a material that suppresses collagen overproduction of fibroblasts in the hair follicle portion of the scalp. Another object of the present invention is to provide a scalp softener containing a collagen overproduction inhibitor.
上記課題を解決するために、発明者らは鋭意検討した結果、アスパラサスリネアリス、イチョウ、イネ、ウコン、ウンシュウミカン、オウレン、ガンビールノキ、キイチゴ、キナノキ、クララ、シナニッケイ、ゲンノショウコ、サンザシ、ショウガ、セイヨウオトギリソウ、セイヨウトチノキ、セイヨウバラ、チョウジ、テンチャ、ドクダミ、ノイバラ、ハマメリス、ヒキオコシ、ヒバマタ、ブドウ、ホップ、マグワ、ユーカリ、ヨーロッパシラカバ及びワレモコウから選ばれる少なくとも１種の植物又はこれらのエキスが、優れたコラーゲン過剰産生抑制作用を有することを見出し、本発明を完成するに至った。 As a result of diligent studies by the inventors to solve the above problems, asparasas linearis, ginkgo, rice, corn, unshu mikan, auren, gambier tree, tree strawberry, kinanoki, clara, shinanikei, gennoshoko, sanzashi, ginger, and sardine , Seiyo Tochinoki, Seiyobara, Chouji, Tencha, Dokudami, Neubara, Hamamelis, Hikiokoshi, Hibamata, Grape, Hop, Magwa, Eucalyptus, European Shirakaba and Waremokou. We have found that it has an overproduction inhibitory effect, and have completed the present invention.
すなわち、本発明は、
（１）アスパラサスリネアリス、イチョウ、イネ、ウコン、ウンシュウミカン、オウレン、ガンビールノキ、キイチゴ、キナノキ、クララ、シナニッケイ、ゲンノショウコ、サンザシ、ショウガ、セイヨウオトギリソウ、セイヨウトチノキ、セイヨウバラ、チョウジ、テンチャ、ドクダミ、ノイバラ、ハマメリス、ヒキオコシ、ヒバマタ、ブドウ、ホップ、マグワ、ユーカリ、ヨーロッパシラカバ及びワレモコウからなる群から選ばれる少なくとも１種の植物又はこれらのエキスを含有することを特徴とする、コラーゲン過剰産生抑制剤、
（２）頭皮に適用される、（１）に記載のコラーゲン過剰産生抑制剤、
（３）（１）又は（２）に記載のコラーゲン過剰産生抑制剤を含む、頭皮柔軟剤、
（４）TGF-β刺激によりコラーゲン産生量が増加した線維芽細胞に対して被験物質を添加し、コラーゲン過剰産生を抑制することを指標として、コラーゲン過剰産生抑制剤又はコラーゲン過剰産生抑制作用に基づく頭皮柔軟剤をスクリーニングする方法、
である。
That is, the present invention
(1) Asparasas linealis, ginkgo, rice, turmeric, unshu mikan, auren, gambiel tree, strawberry, kinanoki, clara, cinnamon, geranium thunbergii, sanzashi, ginger, horse chestnut, horse chestnut, horse chestnut, horse chestnut, horse chestnut, horse chestnut, horse chestnut, horse chestnut , A collagen overproduction inhibitor, characterized by containing at least one plant selected from the group consisting of Houttuynia cordata, Houttuynia cordata, Hibamata, grapes, hops, magwa, eucalyptus, European ginger and Geranium thunbergii, or extracts thereof.
(2) The collagen overproduction inhibitor according to (1), which is applied to the scalp.
(3) A scalp softener containing the collagen overproduction inhibitor according to (1) or (2).
(4) Based on a collagen overproduction inhibitor or a collagen overproduction inhibitory action, with the addition of a test substance to fibroblasts whose collagen production has increased due to TGF-β stimulation and suppression of collagen overproduction as an index. How to screen for scalp softener,
Is.
本発明により、コラーゲン過剰産生抑制剤及びこれを含有する頭皮柔軟剤を提供することができる。 INDUSTRIAL APPLICABILITY According to the present invention, a collagen overproduction inhibitor and a scalp softener containing the same can be provided.
本発明に用いるアスパラサスリネアリス、イチョウ、イネ、ウコン、ウンシュウミカン、オウレン、ガンビールノキ、キイチゴ、キナノキ、クララ、シナニッケイ、ゲンノショウコ、サンザシ、ショウガ、セイヨウオトギリソウ、セイヨウトチノキ、セイヨウバラ、チョウジ、テンチャ、ドクダミ、ノイバラ、ハマメリス、ヒキオコシ、ヒバマタ、ブドウ、ホップ、マグワ、ユーカリ、ヨーロッパシラカバ、及びワレモコウの学名及び使用部位を表１に示す。本発明に用いる各植物は、任意の部位を使用することができるが、表１に記載されている部位を用いることが好ましい。 Asparasas linearis, ginkgo, rice, turmeric, unshu mikan, auren, gambiel tree, raspberry, kinanoki, clara, cinnamon, geranium thunbergii, sanzashi, ginger, horse chestnut, horse chestnut, horse chestnut, horse chestnut, horse chestnut, horse chestnut, horse chestnut, horse chestnut Table 1 shows the scientific names and sites of use of Neubara, Hamamelis, Raspberry, Hibamata, Grape, Hop, Magwa, Eucalyptus, European Clove, and Waremoko. Any part of the plant used in the present invention can be used, but it is preferable to use the parts listed in Table 1.
本発明に用いる各植物は、例えば乾燥刻み加工品を更に細かく粉砕した粉末状の乾燥品としてもよいし、抽出したエキスを使用してもよいが、抽出したエキスを使用するのが好ましい。本発明の植物エキスはどのような方法で抽出されたものでもよく、例えば水、低級脂肪族アルコール（メタノール、エタノール、イソプロピルアルコールなど）、多価アルコール（プロピレングリコール、１，３−ブチレングリコール、グリセリン、ジプロピレングリコールなど）、低級脂肪族ケトン（アセトンなど）などの溶媒により抽出したエキスを使用することができる。 Each plant used in the present invention may be, for example, a powdered dried product obtained by further finely crushing a dried chopped product, or an extracted extract may be used, but it is preferable to use the extracted extract. The plant extract of the present invention may be extracted by any method, for example, water, lower aliphatic alcohols (methanol, ethanol, isopropyl alcohol, etc.), polyhydric alcohols (propylene glycol, 1,3-butylene glycol, glycerin). , Dipropylene glycol, etc.), extracts extracted with solvents such as lower aliphatic ketones (acetone, etc.) can be used.
本発明の植物を水とエタノールからなる溶媒で抽出する場合、溶媒中におけるエタノールの含有量は、30〜90体積％が好ましく、水と１，３−ブチレングリコールからなる溶媒で抽出する場合、溶媒中における１，３−ブチレングリコールの含有量は30〜70体積％が好ましい。 When the plant of the present invention is extracted with a solvent composed of water and ethanol, the content of ethanol in the solvent is preferably 30 to 90% by volume, and when extracted with a solvent composed of water and 1,3-butylene glycol, the solvent is used. The content of 1,3-butylene glycol in the medium is preferably 30 to 70% by volume.
また、本発明の植物エキスの形態は特に制限されるものではなく、加熱処理、凍結乾燥あるいは減圧乾燥などの処理により、乾燥エキス末、エキス末、軟エキス、流エキスなどを使用することができる。なお、本発明に用いるいずれの植物エキスも、本発明のコラーゲン過剰産生抑制作用や頭皮柔軟作用については知られていない。 The form of the plant extract of the present invention is not particularly limited, and dried extract powder, extract powder, soft extract, stream extract and the like can be used by treatment such as heat treatment, freeze-drying or vacuum drying. .. It should be noted that none of the plant extracts used in the present invention is known for the collagen overproduction inhibitory action and the scalp softening action of the present invention.
本発明のコラーゲン過剰産生抑制剤は、化粧品、医薬部外品又は医薬品として提供することができる。投与形態は、頭皮に適用する外用である。その他、試薬として用いることも可能である。 The collagen overproduction inhibitor of the present invention can be provided as a cosmetic product, a quasi drug, or a pharmaceutical product. The dosage form is topical application applied to the scalp. In addition, it can also be used as a reagent.
本発明を外用で適用する場合の剤形としては、例えばシャンプー、コンディショナー、ローション剤、液剤、クリーム剤、軟膏剤、ゲル剤、スプレー剤、石鹸等が挙げられる。これらは、公知の方法で製造することができる。製造に際しては、本発明の効果を損なわない範囲で、化粧品、医薬部外品、医薬品又は試薬に含有可能な種々の添加物を配合することができる。 Examples of the dosage form when the present invention is applied for external use include shampoos, conditioners, lotions, liquids, creams, ointments, gels, sprays, soaps and the like. These can be produced by known methods. In the production, various additives that can be contained in cosmetics, quasi-drugs, pharmaceuticals or reagents can be blended as long as the effects of the present invention are not impaired.
さらに本発明のコラーゲン過剰産生抑制剤は、センブリエキス、ニンジンエキス、トウガラシチンキ、ショウキョウチンキ、ビワ葉エキス、グリチルレチン酸、グリチルリチン酸ジカリウム、グリチルリチン酸モノアンモニウム、パントテン酸、パンテノール、ビタミンE及びその誘導体、ヒノキチオール、サリチル酸、ピロクトンオラミン、ミノキシジル、アデノシン、t-フラバノン、サイトプリン、ペンタデカン酸グリセリド、アラントイン、ニコチン酸アミドをはじめとした発育毛物質と組み合わせて使用することもできる。 Further, the collagen overproduction inhibitor of the present invention includes senburi extract, carrot extract, capsicum tincture, ginger leaf extract, glycyrrhetinic acid, dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, pantothenic acid, panthenol, vitamin E and the like. It can also be used in combination with hair growth substances such as derivatives, hinokithiol, salicylic acid, pyrocton olamine, minoxidyl, adenosine, t-flabanone, cytopurine, pentadecanoic acid glyceride, allantoin, and nicotinamide.
本発明の植物又は植物エキスの配合量は、化粧品、医薬部外品、医薬品又は試薬で提供する場合、組成物全体に対して0.000001〜10質量％、好ましくは0.0001〜5質量％、より好ましくは0.001〜1質量％である。 When provided as a cosmetic, quasi-drug, pharmaceutical or reagent, the amount of the plant or plant extract of the present invention is 0.000001 to 10% by mass, preferably 0.0001 to 5% by mass, more preferably 0.0001 to 5% by mass, based on the entire composition. It is 0.001 to 1% by mass.
また、本発明は、優れたコラーゲン過剰産生抑制剤をスクリーニングする方法を提供するものであり、また、コラーゲン過剰産生抑制作用に基づく頭皮柔軟剤をスクリーニングするための方法を提供するものである。 The present invention also provides a method for screening an excellent collagen overproduction inhibitor, and also provides a method for screening a scalp softener based on a collagen overproduction inhibitory action.
本発明は、TGF-βで刺激しコラーゲン産生を亢進させた線維芽細胞に対して被験物質又は素材を添加し、コラーゲン過剰産生を抑制することを指標として、コラーゲン過剰産生抑制剤又はコラーゲン過剰産生抑制作用に基づく頭皮柔軟剤をスクリーニングする方法である。そして、本発明によりスクリーニングされる頭皮柔軟剤は、TGF-β刺激によるコラーゲン過剰産生を抑制し、頭皮が柔軟化するという新たな作用機序に基づいている。 In the present invention, a collagen overproduction inhibitor or collagen overproduction is used as an index for suppressing collagen overproduction by adding a test substance or material to fibroblasts stimulated with TGF-β to enhance collagen production. It is a method of screening a scalp softener based on an inhibitory effect. The scalp softener screened according to the present invention is based on a new mechanism of action in which TGF-β-stimulated collagen overproduction is suppressed and the scalp is softened.
以下に試験例を挙げ、本発明をさらに具体的に説明するが、本発明は試験例に限定されない。 The present invention will be described in more detail with reference to Test Examples below, but the present invention is not limited to Test Examples.
（試験例１）TGF-β1刺激したヒト線維芽細胞に対するコラーゲン過剰産生抑制作用の評価
＜試験方法＞
ヒト線維芽細胞（倉敷紡績（株））を96穴プレートに1×104細胞/穴の密度で播種し、37℃、CO2 5％にセットしたインキュベーター内で24時間予備培養した。培地には、血清（2体積％）、L-グルタミン及びペニシリン・ストレプトマイシンを含むFibroLife BM基礎培地（倉敷紡績（株））を用いた。予備培養後、PBSにて細胞表面を洗浄した後、下記の通りに培地を添加した。無刺激群には、溶媒（１，３−ブチレングリコール又はエタノール）の終濃度が各植物エキス群と同一となるように溶媒を含有した無血清培地を添加した。TGF-β1刺激（対照）群には、コラーゲン産生を亢進させるためにTGF-β1（10ng/mL）を加え、さらに溶媒（１，３−ブチレングリコール又はエタノール）の終濃度が各植物エキス群と同一となるように溶媒を加えた無血清培地を添加した。各植物エキス群には、コラーゲン過剰産生抑制作用を評価する素材として植物エキス（10μg/mL）を加え、さらにTGF-β1（10ng/mL）を加えた無血清培地を添加した。培地交換後、72時間培養した。その後、培地を回収し、コラーゲン産生量の測定に用いた。培地回収後の細胞に、M-PER Mammalian Protein Extraction Reagent（サーモフィッシャーサイエンティフィック（株））を添加して細胞溶解液を回収し、細胞蛋白質量の測定に用いた。コラーゲン産生量は、Procollagen type I C-peptide (PIP) EIA Kit（タカラバイオ（株））を用いて、取扱説明書の手順に従い測定した。細胞蛋白質量は、BCA protein assay reagent kit（サーモフィッシャーサイエンティフィック（株））を用いて、取扱説明書の手順に従い測定した。コラーゲン産生量の測定値は、細胞蛋白質量当たりのPIP量（ng/μg protein）とした。各穴のコラーゲン産生量の測定値から、各群3穴の平均値及び標準誤差を算出した。なお、１，３−ブチレングリコール及びエタノールの終濃度は、細胞に対して毒性を示さないようにいずれも0.5体積％以下とした。
(Test Example 1) Evaluation of collagen overproduction inhibitory effect on TGF-β1-stimulated human fibroblasts <Test method>
Human fibroblasts (Kurabo Industries, Ltd.) were seeded at a density of 1 × 10 4 cells / well in 96-well plates, 37 ° C., for 24 hours pre-incubation in an incubator set at CO 2 5%. As the medium, FibroLife BM basal medium (Kurashiki Spinning Co., Ltd.) containing serum (2% by volume), L-glutamine and penicillin streptomycin was used. After pre-culture, the cell surface was washed with PBS, and then the medium was added as follows. To the non-stimulation group, a serum-free medium containing the solvent was added so that the final concentration of the solvent (1,3-butylene glycol or ethanol) was the same as that of each plant extract group. TGF-β1 (10 ng / mL) was added to the TGF-β1 stimulated (control) group to enhance collagen production, and the final concentration of the solvent (1,3-butylene glycol or ethanol) was higher than that of each plant extract group. A serum-free medium containing a solvent was added so as to be the same. To each plant extract group, a plant extract (10 μg / mL) was added as a material for evaluating the collagen overproduction inhibitory effect, and a serum-free medium containing TGF-β1 (10 ng / mL) was further added. After changing the medium, the cells were cultured for 72 hours. Then, the medium was collected and used for measuring the amount of collagen produced. M-PER Mammalian Protein Extraction Reagent (Thermo Fisher Scientific Co., Ltd.) was added to the cells after collecting the medium, and the cell lysate was collected and used for measuring the cell protein mass. The amount of collagen produced was measured using a Procollagen type I C-peptide (PIP) EIA Kit (Takara Bio Inc.) according to the procedure in the instruction manual. The cell protein mass was measured using the BCA protein assay reagent kit (Thermo Fisher Scientific Co., Ltd.) according to the procedure in the instruction manual. The measured value of collagen production was the amount of PIP (ng / μg protein) per cell protein mass. From the measured values of collagen production in each hole, the average value and standard error of 3 holes in each group were calculated. The final concentrations of 1,3-butylene glycol and ethanol were set to 0.5% by volume or less so as not to show toxicity to cells.
＜結果＞
図１は、TGF-β1刺激（対照）群のコラーゲン産生量と、無刺激群のコラーゲン産生量を示した図である。コラーゲン産生量の測定値（ng/μg protein）は、無刺激群で12.35±0.62、TGF-β1刺激（対照）群で26.79±0.69であり、TGF-β1刺激（対照）群でコラーゲン産生の有意な亢進が認められた。
図２〜図５は、本発明の各植物エキスのコラーゲン過剰産生抑制効果を示した図である。図２では、コラーゲン過剰産生抑制効果について、TGF-β1刺激（対照）群のコラーゲン産生量を100％として、各植物エキス群のコラーゲン産生量の相対値（平均値±標準誤差）で示した（溶媒：0.1％１，３−ブチレングリコール）。図１に示したTGF-β1刺激（対照）群のコラーゲン産生量の測定値（ng/μg protein）は26.79±0.69であり、このTGF-β1刺激（対照）群のコラーゲン産生量を100％として図２に示した。図２から明らかなように、各植物エキスはコラーゲン過剰産生抑制効果を示した。
図３では、コラーゲン過剰産生抑制効果について、TGF-β1刺激（対照）群のコラーゲン産生量を100％として、各植物エキス群のコラーゲン産生量の相対値（平均値±標準誤差）で示した（溶媒：0.3％１，３−ブチレングリコール）。図３から明らかなように、イネ、ドクダミのエキスはコラーゲン過剰産生抑制効果を示した。なお、コラーゲン産生量の測定値（ng/μg protein）は、無刺激群で8.77±0.08（ng/μg protein）、TGF-β1刺激（対照）群で12.97±1.11（ng/μg protein）であり、TGF-β1刺激（対照）群でコラーゲン産生の有意な亢進が認められた。
図４では、コラーゲン過剰産生抑制効果について、TGF-β1刺激（対照）群のコラーゲン産生量を100％として、各植物エキス群のコラーゲン産生量の相対値（平均値±標準誤差）で示した（溶媒：0.1％エタノール）。図４から明らかなように、シナニッケイ、ショウガのエキスはコラーゲン過剰産生抑制効果を示した。なお、コラーゲン産生量の測定値（ng/μg protein）は、無刺激群で7.12±0.81、TGF-β1刺激（対照）群で13.63±1.13であり、TGF-β1刺激（対照）群でコラーゲン産生の有意な亢進が認められた。
図５では、コラーゲン過剰産生抑制効果について、TGF-β1刺激（対照）群のコラーゲン産生量を100％として、各植物エキス群のコラーゲン産生量の相対値（平均値±標準誤差）で示した（溶媒：0.5％エタノール）。図５から明らかなように、チョウジのエキスはコラーゲン過剰産生抑制効果を示した。なお、コラーゲン産生量の測定値（ng/μg protein）は、無刺激群で8.59±0.26、TGF-β1刺激（対照）群で12.77±1.54であり、TGF-β1刺激（対照）群でコラーゲン産生の亢進が認められた。
<Result>
FIG. 1 is a diagram showing the amount of collagen produced in the TGF-β1 stimulated (control) group and the amount of collagen produced in the non-stimulated group. The measured value of collagen production (ng / μg protein) was 12.35 ± 0.62 in the unstimulated group and 26.79 ± 0.69 in the TGF-β1 stimulated (control) group, and the significant collagen production in the TGF-β1 stimulated (control) group. Increased activity was observed.
2 to 5 are views showing the collagen overproduction inhibitory effect of each plant extract of the present invention. In FIG. 2, the collagen overproduction inhibitory effect is shown as a relative value (average value ± standard error) of the collagen production amount of each plant extract group, assuming that the collagen production amount of the TGF-β1 stimulation (control) group is 100% (mean value ± standard error). Solvent: 0.1% 1,3-butylene glycol). The measured value (ng / μg protein) of collagen production in the TGF-β1 stimulated (control) group shown in FIG. 1 was 26.79 ± 0.69, and the collagen production in this TGF-β1 stimulated (control) group was taken as 100%. It is shown in FIG. As is clear from FIG. 2, each plant extract showed an effect of suppressing collagen overproduction.
In FIG. 3, the collagen overproduction inhibitory effect is shown as a relative value (mean ± standard error) of the collagen production amount of each plant extract group, assuming that the collagen production amount of the TGF-β1 stimulation (control) group is 100% (mean value ± standard error). Solvent: 0.3% 1,3-butylene glycol). As is clear from FIG. 3, the rice and Houttuynia cordata extracts showed a collagen overproduction inhibitory effect. The measured collagen production (ng / μg protein) was 8.77 ± 0.08 (ng / μg protein) in the non-stimulated group and 12.97 ± 1.11 (ng / μg protein) in the TGF-β1 stimulated (control) group. , TGF-β1 stimulation (control) group showed a significant increase in collagen production.
In FIG. 4, the collagen overproduction inhibitory effect is shown as a relative value (mean ± standard error) of the collagen production amount of each plant extract group, assuming that the collagen production amount of the TGF-β1 stimulation (control) group is 100% (mean value ± standard error). Solvent: 0.1% ethanol). As is clear from FIG. 4, the extracts of Chinese cinnamon and ginger showed an inhibitory effect on collagen overproduction. The measured values of collagen production (ng / μg protein) were 7.12 ± 0.81 in the non-stimulated group and 13.63 ± 1.13 in the TGF-β1 stimulated (control) group, and collagen production in the TGF-β1 stimulated (control) group. Significant increase in collagen was observed.
In FIG. 5, the collagen overproduction inhibitory effect is shown as a relative value (mean ± standard error) of the collagen production amount of each plant extract group, assuming that the collagen production amount of the TGF-β1 stimulation (control) group is 100% (mean value ± standard error). Solvent: 0.5% ethanol). As is clear from FIG. 5, the clove extract showed an effect of suppressing collagen overproduction. The measured values of collagen production (ng / μg protein) were 8.59 ± 0.26 in the non-stimulated group and 12.77 ± 1.54 in the TGF-β1 stimulated (control) group, and collagen production in the TGF-β1 stimulated (control) group. Was observed to increase.
表２に、検定結果を示す。各植物エキスは、TGF-β1刺激（対照）群と比較して線維芽細胞のコラーゲン産生量を有意に抑制した。 Table 2 shows the test results. Each plant extract significantly suppressed the amount of collagen produced by fibroblasts as compared with the TGF-β1 stimulated (control) group.
以上の結果から、アスパラサスリネアリス、イチョウ、イネ、ウコン、ウンシュウミカン、オウレン、ガンビールノキ、キイチゴ、キナノキ、クララ、シナニッケイ、ゲンノショウコ、サンザシ、ショウガ、セイヨウオトギリソウ、セイヨウトチノキ、セイヨウバラ、チョウジ、テンチャ、ドクダミ、ノイバラ、ハマメリス、ヒキオコシ、ヒバマタ、ブドウ、ホップ、マグワ、ユーカリ、ヨーロッパシラカバ、又はワレモコウのエキスは、線維芽細胞におけるコラーゲン過剰産生を抑制する効果を有することが明らかとなった。本試験結果に基づけば、本発明のコラーゲン過剰産生抑制剤は、頭皮の毛包に適用すると、TGF-β刺激による線維芽細胞の過剰なコラーゲン産生を抑制すると考えられるので、アスパラサスリネアリス、イチョウ、イネ、ウコン、ウンシュウミカン、オウレン、ガンビールノキ、キイチゴ、キナノキ、クララ、シナニッケイ、ゲンノショウコ、サンザシ、ショウガ、セイヨウオトギリソウ、セイヨウトチノキ、セイヨウバラ、チョウジ、テンチャ、ドクダミ、ノイバラ、ハマメリス、ヒキオコシ、ヒバマタ、ブドウ、ホップ、マグワ、ユーカリ、ヨーロッパシラカバ及びワレモコウのエキスは頭皮柔軟化効果を有すると推察される。 From the above results, asparasas linealis, ginkgo, rice, eucalyptus, unshu mikan, auren, gambiel tree, strawberry, kinanoki, clara, cinnamon, geranium thunbergii, ginger, horse chestnut, horse chestnut, horse chestnut, horse chestnut, horse chestnut, horse chestnut, horse chestnut, horse chestnut. , Equisetum arvense, Houttuynia cordata, Houttuynia cordata, grapes, hops, magwa, eucalyptus, European cinnamon, or Geranium thunbergii have been shown to have the effect of suppressing collagen overproduction in fibroblasts. Based on the results of this test, it is considered that the collagen overproduction inhibitor of the present invention suppresses the excessive collagen production of fibroblasts stimulated by TGF-β when applied to the hair follicles of the scalp. Therefore, asparasas linearis and geranium thunbergii , Rice, Ukon, Unshuumikan, Ouren, Ganbeiruki, Kistrawberry, Kinanoki, Clara, Shinanikkei, Geranium thunbergii, Sanzashi, Geranium, Geranium thunbergii, Geranium thunbergii, Houttuynia cordata, Houttuynia cordata, Chouji, Tencha, Houttuynia cordata, Houttuynia cordata, Houttuynia cordata , Hop, magwa, eucalyptus, European white birch and Houttuynia cordata extract are presumed to have a scalp softening effect.
本発明のアスパラサスリネアリス、イチョウ、イネ、ウコン、ウンシュウミカン、オウレン、ガンビールノキ、キイチゴ、キナノキ、クララ、シナニッケイ、ゲンノショウコ、サンザシ、ショウガ、セイヨウオトギリソウ、セイヨウトチノキ、セイヨウバラ、チョウジ、テンチャ、ドクダミ、ノイバラ、ハマメリス、ヒキオコシ、ヒバマタ、ブドウ、ホップ、マグワ、ユーカリ、ヨーロッパシラカバ及びワレモコウのエキスは、線維芽細胞の過剰なコラーゲン産生、特にTGF-β刺激によるものを抑制する効果を有するため、頭皮を柔軟化するための化粧品、医薬部外品又は医薬品等の分野に利用可能である。また、本発明のコラーゲン過剰産生抑制剤を含む、頭皮柔軟剤は、素材スクリーニング等を行なう際に、陽性対照薬として用いることができる。 Asparasas linealis, ginger, rice, turmeric, unshu mikan, auren, gan beer tree, strawberry, kinanoki, clara, cinnamon, geranium thunbergii, sardine, ginger, horse chestnut, horse chestnut, horse chestnut, horse chestnut, horse chestnut, horse chestnut, horse chestnut, horse chestnut , Hamamelis, Hikiokoshi, Hibamata, Grape, Hop, Magwa, Eucalyptus, European Ginger and Waremoko extract have the effect of suppressing excessive collagen production in fibroblasts, especially due to TGF-β stimulation, thus softening the scalp. It can be used in the fields of cosmetics, quasi-drugs, pharmaceuticals, etc. In addition, the scalp softener containing the collagen overproduction inhibitor of the present invention can be used as a positive control agent when performing material screening and the like.
Claims (3)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015206939 | 2015-10-21 | ||
| JP2015206939 | 2015-10-21 | ||
| JP2016202206A JP6874320B2 (en) | 2015-10-21 | 2016-10-14 | Scalp agent |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016202206A Division JP6874320B2 (en) | 2015-10-21 | 2016-10-14 | Scalp agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021006586A true JP2021006586A (en) | 2021-01-21 |
| JP7421465B2 JP7421465B2 (en) | 2024-01-24 |
Family
ID=58665856
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016202206A Active JP6874320B2 (en) | 2015-10-21 | 2016-10-14 | Scalp agent |
| JP2020176421A Pending JP2021006587A (en) | 2015-10-21 | 2020-10-21 | Scalp agents |
| JP2020176418A Active JP7421463B2 (en) | 2015-10-21 | 2020-10-21 | Scalp preparation |
| JP2020176420A Active JP7421465B2 (en) | 2015-10-21 | 2020-10-21 | Scalp preparation |
| JP2020176419A Active JP7421464B2 (en) | 2015-10-21 | 2020-10-21 | Scalp preparation |
| JP2021176826A Active JP7264200B2 (en) | 2015-10-21 | 2021-10-28 | scalp agent |
| JP2021176827A Active JP7264201B2 (en) | 2015-10-21 | 2021-10-28 | scalp agent |
| JP2021177034A Pending JP2022023191A (en) | 2015-10-21 | 2021-10-29 | Scalp agents |
| JP2023026182A Pending JP2023054253A (en) | 2015-10-21 | 2023-02-22 | Scalp agents |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016202206A Active JP6874320B2 (en) | 2015-10-21 | 2016-10-14 | Scalp agent |
| JP2020176421A Pending JP2021006587A (en) | 2015-10-21 | 2020-10-21 | Scalp agents |
| JP2020176418A Active JP7421463B2 (en) | 2015-10-21 | 2020-10-21 | Scalp preparation |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020176419A Active JP7421464B2 (en) | 2015-10-21 | 2020-10-21 | Scalp preparation |
| JP2021176826A Active JP7264200B2 (en) | 2015-10-21 | 2021-10-28 | scalp agent |
| JP2021176827A Active JP7264201B2 (en) | 2015-10-21 | 2021-10-28 | scalp agent |
| JP2021177034A Pending JP2022023191A (en) | 2015-10-21 | 2021-10-29 | Scalp agents |
| JP2023026182A Pending JP2023054253A (en) | 2015-10-21 | 2023-02-22 | Scalp agents |
Country Status (1)
| Country | Link |
|---|---|
| JP (9) | JP6874320B2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110693773A (en) * | 2018-07-09 | 2020-01-17 | 株式会社Lg生活健康 | Composition for preventing alopecia or promoting hair growth |
| JP6921284B1 (en) * | 2020-09-01 | 2021-08-18 | 株式会社 資生堂 | Adenosine-containing composition and a method for suppressing the precipitation of adenosine |
| CN112370393B (en) * | 2020-12-10 | 2022-09-06 | 泉后(广州)生物科技研究院有限公司 | Hair washing mousse composition and preparation method and application thereof |
| JP6988016B1 (en) * | 2021-04-22 | 2022-01-05 | 佐藤製薬株式会社 | Granzyme B inhibitor |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1067674A (en) * | 1996-06-19 | 1998-03-10 | Advanced Sukin Res Kenkyusho:Kk | Abnormal accumulation suppressor of extracellular matrix |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0578222A (en) * | 1991-05-01 | 1993-03-30 | Sansho Seiyaku Co Ltd | Preventive for gray hair |
| JP3241609B2 (en) * | 1996-09-20 | 2001-12-25 | サントリー株式会社 | Pharmaceuticals containing bean tea extract as an active ingredient, and foods and cosmetics containing the same |
| JP3441722B2 (en) | 2000-12-22 | 2003-09-02 | 株式会社資生堂 | Cosmetics |
| JP2002316917A (en) * | 2001-04-19 | 2002-10-31 | Naris Cosmetics Co Ltd | Hair tonic/hair growing agent, gray hair improving cosmetic |
| JP2002316937A (en) | 2001-04-19 | 2002-10-31 | Ichimaru Pharcos Co Ltd | Plant extract-containing anti-allergic agent |
| JP2003171240A (en) | 2001-09-28 | 2003-06-17 | Lion Corp | Gray hair prophylactic/ameliorating agent and method for screening hair active ingredient |
| JP2004175734A (en) * | 2002-11-28 | 2004-06-24 | Kose Corp | Dermopathy inhibitor, dermopathy-improving agent, and skin care preparation for external use containing them |
| JP2005281284A (en) | 2004-03-26 | 2005-10-13 | Ivy Cosmetics Corp | Skin care preparation for external use for promoting collagen synthesis |
| JP2008179576A (en) * | 2007-01-25 | 2008-08-07 | Yoshiro Nakamatsu | Medicated hair grower |
| JP2009084255A (en) | 2007-10-03 | 2009-04-23 | Cosmetics Roorando Kk | External medical composition for hair growth inhibition |
| JP2011068583A (en) * | 2009-09-25 | 2011-04-07 | Shiseido Co Ltd | Protein glycation inhibitor |
| JP5675178B2 (en) | 2010-06-09 | 2015-02-25 | 大島 光宏 | Collagen degradation inhibitor |
| JP5890100B2 (en) * | 2011-02-09 | 2016-03-22 | 雪印メグミルク株式会社 | Skin collagen production promoter |
| JP6217038B2 (en) * | 2012-02-03 | 2017-10-25 | 学校法人同志社 | Protein saccharification reaction inhibitor |
| JP2016056116A (en) | 2014-09-08 | 2016-04-21 | 株式会社ディーエイチシー | Composition for promoting collagen production |
-
2016
- 2016-10-14 JP JP2016202206A patent/JP6874320B2/en active Active
-
2020
- 2020-10-21 JP JP2020176421A patent/JP2021006587A/en active Pending
- 2020-10-21 JP JP2020176418A patent/JP7421463B2/en active Active
- 2020-10-21 JP JP2020176420A patent/JP7421465B2/en active Active
- 2020-10-21 JP JP2020176419A patent/JP7421464B2/en active Active
-
2021
- 2021-10-28 JP JP2021176826A patent/JP7264200B2/en active Active
- 2021-10-28 JP JP2021176827A patent/JP7264201B2/en active Active
- 2021-10-29 JP JP2021177034A patent/JP2022023191A/en active Pending
-
2023
- 2023-02-22 JP JP2023026182A patent/JP2023054253A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1067674A (en) * | 1996-06-19 | 1998-03-10 | Advanced Sukin Res Kenkyusho:Kk | Abnormal accumulation suppressor of extracellular matrix |
Non-Patent Citations (3)
| Title |
|---|
| BALANCING SCALP NOURISH CONDITIONER,ID 2353634 ,MINTEL GNPD[ONLINE],2014年5月 ,[検索日2021.08.12]，, JPN6021034298, ISSN: 0004841952 * |
| LOTION FEMME,ID3271837 ,MINTEL GNPD[ONLINE],2015年6月,[検索日2021.08.12]，ＵＲＬ，HTTPS://WWW.PORTAL, JPN6021034297, ISSN: 0004841953 * |
| STIMULATING SCALP TREAT,ID 1178198 ,MINTEL GNPD[ONLINE],2009年9月,[検索日2021.08.12]，ＵＲＬ，HTTPS, JPN6021034299, ISSN: 0004841951 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022023191A (en) | 2022-02-07 |
| JP2021006584A (en) | 2021-01-21 |
| JP7421463B2 (en) | 2024-01-24 |
| JP2021006587A (en) | 2021-01-21 |
| JP2022023187A (en) | 2022-02-07 |
| JP2021006585A (en) | 2021-01-21 |
| JP2022023188A (en) | 2022-02-07 |
| JP7421465B2 (en) | 2024-01-24 |
| JP7264201B2 (en) | 2023-04-25 |
| JP2017078061A (en) | 2017-04-27 |
| JP6874320B2 (en) | 2021-05-19 |
| JP7421464B2 (en) | 2024-01-24 |
| JP7264200B2 (en) | 2023-04-25 |
| JP2023054253A (en) | 2023-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021006586A (en) | Scalp agents | |
| Fronza et al. | Determination of the wound healing effect of Calendula extracts using the scratch assay with 3T3 fibroblasts | |
| TWI740861B (en) | Hair growth/hair growth promoter | |
| Alexander et al. | Migration and proliferation effects of thymoquinone-loaded nanostructured lipid carrier (Tq-Nlc) and thymoquinone (Tq) on in vitro wound healing models | |
| US20230201104A1 (en) | Virus inactivating agent | |
| CN107530273A (en) | Composition containing Valerian root P.E | |
| JP4101106B2 (en) | Moisturizing plant extract and external preparation, cosmetic, bath preparation and cleaning agent containing the extract | |
| JP2006241148A (en) | Collagenase inhibitor and external preparation for skin for preventing aging | |
| JP2006347902A (en) | Moisture retention plant extract, and external preparation, cosmetic product, bathing agent and detergent containing the extract | |
| JP2006342067A (en) | Moisturizing plant extract, and external preparation, cosmetic, bathing agent and detergent each containing the extract | |
| JP2009235044A (en) | ENDOTHELIN-1 mRNA EXPRESSION INHIBITOR, MATRIX METALLOPROTEASE-9 mRNA EXPRESSION INHIBITOR, COLLAGEN PRODUCTION PROMOTER, PROFILAGGRIN PRODUCTION PROMOTER, FILAGGRIN PRODUCTION PROMOTER AND AQUAPORIN 3 mRNA EXPRESSION PROMOTER | |
| JP2006347907A (en) | Moisture retention plant extract, and external preparation, cosmetic product, bathing agent and detergent containing the extract | |
| JP2019194176A (en) | R-spondin 1 production promoter | |
| JP2006342068A (en) | Moisturizing plant extract, and external preparation, cosmetic, bathing agent and detergent each containing the extract | |
| JP2007325693A (en) | Deodorant, and deodorizing product containing this deodorant | |
| JP2004315442A (en) | Gray hair-preventing/improving agent | |
| JP2006347905A (en) | Moisture retention plant extract, and external preparation, cosmetic product, bathing agent and detergent containing the extract | |
| JP2006342069A (en) | Moisturizing plant extract, and external preparation, cosmetic, bathing agent and detergent each containing the extract | |
| JP2006111631A (en) | Medicine for alleviating itchy skin, rough skin, sensitive skin and bleaching by controlling production/release of stem cell factor | |
| JP2020066618A (en) | Composition for treating wound comprising gypenoside lxxv as active ingredient | |
| KR101548254B1 (en) | Composition for treating skin disease comprising sulfur, alum and vinegar | |
| JP2019206490A (en) | Mixed component having 5α-reductase inhibitory action, and composition for hair growth containing the same | |
| JP2006342070A (en) | Moisturizing plant extract, and external preparation, cosmetic, bathing agent and detergent each containing the extract | |
| JP6527005B2 (en) | Deodorant composition, external preparation for skin containing the deodorant composition | |
| KELLOU et al. | Phytocosmetics: A literature review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201021 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210907 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211029 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220322 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220610 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220610 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220617 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220621 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20220805 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20220809 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231115 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240112 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7421465 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |